|
1
|
Osborne CK and Schiff R: Estrogen-receptor
biology: continuing progress and therapeutic implications. J Clin
Oncol. 23:1616–1622. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Osborne CK, Zhao H and Fuqua SA: Selective
estrogen receptor modulators: structure, function, and clinical
use. J Clin Oncol. 18:3172–3186. 2000.PubMed/NCBI
|
|
3
|
Harvey JM, Clark GM, Osborne CK and Allred
DC: Estrogen receptor status by immunohistochemistry is superior to
the ligand-binding assay for predicting response to adjuvant
endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481.
1999.PubMed/NCBI
|
|
4
|
Herynk MH and Fuqua SA: Estrogen receptors
in resistance to hormone therapy. Adv Exp Med Biol. 608:130–143.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Milano A, Dal Lago L, Sotiriou C, Piccart
M and Cardoso F: What clinicians need to know about antioestrogen
resistance in breast cancer therapy. Eur J Cancer. 42:2692–2705.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ali S and Coombes RC: Endocrine-responsive
breast cancer and strategies for combating resistance. Nat Rev
Cancer. 2:101–112. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kurebayashi J: Endocrine-resistant breast
cancer: underlying mechanisms and strategies for overcoming
resistance. Breast Cancer. 10:112–119. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schiff R, Massarweh S, Shou J and Osborne
CK: Breast cancer endocrine resistance: how growth factor signaling
and estrogen receptor coregulators modulate response. Clin Cancer
Res. 9:447S–454S. 2003.PubMed/NCBI
|
|
9
|
Dekker LV and Parker PJ: Protein kinase C
- a question of specificity. Trends Biochem Sci. 19:73–77. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fabbro D, Kung W, Roos W, Regazzi R and
Eppenberger U: Epidermal growth factor binding and protein kinase C
activities in human breast cancer cell lines: possible quantitative
relationship. Cancer Res. 46:2720–2725. 1986.
|
|
11
|
Boyan BD, Sylvia VL, Frambach T, Lohmann
CH, Dietl J, Dean DD and Schwartz Z: Estrogen-dependent rapid
activation of protein kinase C in estrogen receptor-positive MCF-7
breast cancer cells and estrogen receptor-negative HCC38 cells is
membrane-mediated and inhibited by tamoxifen. Endocrinology.
144:1812–1824. 2003. View Article : Google Scholar
|
|
12
|
Gordge PC, Hulme MJ, Clegg RA and Miller
WR: Elevation of protein kinase A and protein kinase C activities
in malignant as compared with normal human breast tissue. Eur J
Cancer. 32A:2120–2126. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim S, Han J, Lee SK, Choi MY, Kim J, Lee
J, Jung SP, Kim JS, Kim JH, Choe JH, Lee JE and Nam SJ: Berberine
suppresses the TPA-induced MMP-1 and MMP-9 expressions through the
inhibition of PKC-α in breast cancer cells. J Surg Res.
176:e21–e29. 2012.PubMed/NCBI
|
|
14
|
Knowlden JM, Hutcheson IR, Jones HE,
Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE and Nicholson
RI: Elevated levels of epidermal growth factor receptor/c-erbB2
heterodimers mediate an autocrine growth regulatory pathway in
tamoxifen-resistant MCF-7 cells. Endocrinology. 144:1032–1044.
2003. View Article : Google Scholar
|
|
15
|
Hodges RR, Kazlauskas A, Toker A and Dartt
DA: Effect of overexpression of protein kinase C alpha on rat
lacrimal gland protein secretion. Adv Exp Med Biol. 506:237–241.
2002.PubMed/NCBI
|
|
16
|
Kikkawa U, Takai Y, Tanaka Y, Miyake R and
Nishizuka Y: Protein kinase C as a possible receptor protein of
tumor-promoting phorbol esters. J Biol Chem. 258:11442–11445.
1983.PubMed/NCBI
|
|
17
|
Osborne CK: Tamoxifen in the treatment of
breast cancer. N Engl J Med. 339:1609–1618. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Newton AC: Protein kinase C: structure,
function, and regulation. J Biol Chem. 270:28495–28498. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gupta AK, Galoforo SS, Berns CM, Martinez
AA, Corry PM, Guan KL and Lee YJ: Elevated levels of ERK2 in human
breast carcinoma MCF-7 cells transfected with protein kinase C
alpha. Cell Prolif. 29:655–663. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tonetti DA, O’Regan R, Tanjore S, England
G and Jordan VC: Antiestrogen stimulated human endometrial cancer
growth: laboratory and clinical considerations. J Steroid Biochem
Mol Biol. 65:181–189. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McInerney EM, Weis KE, Sun J, Mosselman S
and Katzenellenbogen BS: Transcription activation by the human
estrogen receptor subtype β (ERβ) studied with ERβ and ERα receptor
chimeras. Endocrinology. 139:4513–4522. 1998.
|
|
22
|
Basu A: The potential of protein kinase C
as a target for anticancer treatment. Pharmacol Ther. 59:257–280.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Blobe GC, Obeid LM and Hannun YA:
Regulation of protein kinase C and role in cancer biology. Cancer
Metastasis Rev. 13:411–431. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ways DK, Kukoly CA, deVente J, Hooker JL,
Bryant WO, Posekany KJ, Fletcher DJ, Cook PP and Parker PJ: MCF-7
breast cancer cells transfected with protein kinase C-alpha exhibit
altered expression of other protein kinase C isoforms and display a
more aggressive neoplastic phenotype. J Clin Invest. 95:1906–1915.
1995. View Article : Google Scholar
|
|
25
|
Kushner PJ, Agard DA, Greene GL, Scanlan
TS, Shiau AK, Uht RM and Webb P: Estrogen receptor pathways to
AP-1. J Steroid Biochem Mol Biol. 74:311–317. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jonat C, Rahmsdorf HJ, Park KK, Cato AC,
Gebel S, Ponta H and Herrlich P: Antitumor promotion and
antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by
glucocorticoid hormone. Cell. 62:1189–1204. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Behrens A, Jochum W, Sibilia M and Wagner
EF: Oncogenic transformation by ras and fos is mediated by c-Jun
N-terminal phosphorylation. Oncogene. 19:2657–2663. 2000.
View Article : Google Scholar : PubMed/NCBI
|
